Results 21 to 30 of about 963 (180)

The Efficacy and Safety of Bilastine in the Treatment of Perennial Allergic Rhinitis in Patients with Moderate and Severe Forms of the Disease. Comparison of bilastine 20 mg with desloratadine 5 mg Сергей [PDF]

Медицинский совет, 2019
Background: Bilastine is a new non-sedating H1 antihistamine approved for the symptomatic treatment of allergic rhinoconjunctivitis (ARC) and urticaria in adults and children over 12 years of age.
S. Ryazantsev, I. Gogunska, I. Lymar, L. Romanyuk, B. Bil, S. Pukhlik, V. Pravdyva, V. Lapshyn, V. Koshlia   +8 more
doaj   +2 more sources

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study

Clinical Ophthalmology, 2023
Piotr Kuna,1 Marek Jutel,2,3 Grazyna Pulka,4 Slawomir Tokarski,5 Paula Arranz,6 Gonzalo Hernández,6 Nieves Fernández Hernando6 1Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland; 2Department of Clinical ...
Kuna P, Jutel M, Pulka G, Tokarski S, Arranz P, Hernández G, Fernández Hernando N   +6 more
doaj   +2 more sources

Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice [PDF]

International Journal of Molecular Sciences, 2019
Diabetic nephropathy is an unmet therapeutic need, and the search for new therapeutic strategies is warranted. Previous data point to histamine H1 receptor as a possible target for glomerular dysfunction associated with long term hyperglycaemia. Therefore, this study investigated the effects of the H1 receptor antagonist bilastine on renal morphology ...
Verta R., Grange C., Gurrieri M., Borga S., Nardini P., Argenziano M., Ghe C., Cavalli R., Benetti E., Miglio G., Bussolati B., Pini A., Rosa A. C.   +12 more
openaire   +4 more sources

Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions [PDF]

Drugs in R&D
Background and Objective Orodispersible tablets (ODT) rapidly dissolve in the oral cavity and can improve patient’s convenience. This pharmacokinetic study assessed the bioequivalence of a novel 20 mg ODT formulation of bilastine compared with bilastine ...
Manuel Román, Dolores Ochoa, Samuel Martin, Sergio Luquero, Inmaculada Gilaberte, Paula Arranz, Carlos Sánchez   +6 more
doaj   +2 more sources

Levocetirizine versus Bilastine as Monotherapy in the Management of Chronic Spontaneous Urticaria: A Randomised Controlled Trial [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Chronic urticaria is defined as the almost daily occurrence of wheals and pruritus for a minimum of six weeks, adversely affecting the quality of life and necessitating management with a drug with better efficacy and a high safety profile ...
Roshini Rajendran, VNS Ahamed Shariff, Vijayabhaskar Chandran, Deepa Kalappan   +3 more
doaj   +2 more sources

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK-air Study. [PDF]

Clin Exp Allergy
This mHealth study has shown that fixed combinations of intranasal antihistamines and corticosteroids were associated with higher quality of life than oral antihistamines and intranasal antihistamines. Both intranasal corticosteroids and oral antihistamines were associated with higher quality of life than intranasal antihistamines.
Lourenço-Silva N, Sousa-Pinto B, Bognanni A, Pereira AM, Coutinho-Almeida J, Amaral R, Brussino L, Giovannini M, Gemicioglu B, Kvedariene V, Larenas-Linnemann DE, Marques-Cruz M, Papadopoulos NG, Pham-Thi N, Regateiro FS, Toppila-Salmi SK, Samolinski B, Sastre J, Taborda-Barata L, Valiulis A, Vecillas LL, Ventura MT, Pfaar O, Fonseca JA, Zuberbier T, Klimek L, Bousquet J, Vieira RJ.   +27 more
europepmc   +2 more sources

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Drugs in Context, 2021
Background: Bilastine, a non-sedating H1-antihistamine, is indicated to treat the symptoms of allergic disorders (e.g. rhinoconjunctivitis and urticaria) in adults and adolescents and, more recently, in children.
Amalia Leceta, Aintzane García, Ander Sologuren, Cristina Campo   +3 more
doaj   +1 more source

Pregnancy Outcome Following First-Trimester Exposure to Bilastine: A Comparative Observational Cohort Study from the Israeli Teratology Information Service. [PDF]

J Clin Med
Background: Bilastine is a long-acting, nonsedating antihistamine used to treat allergic conditions. Human pregnancy experience with bilastine remains limited.
Hegla-Murad R, Shechtman S, Diav-Citrin O.   +2 more
europepmc   +2 more sources

Bilastine

Reactions Weekly, 2018
Bilastine is a new second generation H1-antihistamine approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU) in patients older than 12 years of age. AR and urticaria are very common clinical conditions that represent one of the most frequent reasons for a patient to visit their general ...
Jeet Gandhi, Kiran Godse, Gauri Godse
  +4 more sources

Comparative clinical assessment of updosing of bilastine and combination of levocetirizine and hydroxyzine in chronic spontaneous urticaria

Clinical Dermatology Review, 2022
Background: Second-generation antihistamines (SGAHs) are first-line drugs in management of chronic spontaneous urticaria (CSU). However, almost 50% of the patients do not respond to standard dose of SGAH.
Bela Shah, Deval Mistry, Neha Jangid, Shikha Shah, Shruti Kamat, Dhiraj Dhoot, Gaurav Deshmukh   +6 more
doaj   +1 more source